2-chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients
- 1 October 1997
- journal article
- case report
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 29 (4) , 288-292
- https://doi.org/10.1002/(sici)1096-911x(199710)29:4<288::aid-mpo9>3.0.co;2-i
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Langerhans cell histiocytosisThe Journal of Pediatrics, 1995
- 2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis XNew England Journal of Medicine, 1993
- Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concernThe Journal of Pediatrics, 1991
- 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive NucleosideLeukemia & Lymphoma, 1991
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.Journal of Clinical Investigation, 1990
- The Frequency and Natural History of Diabetes Insipidus in Children with Langerhans-Cell HistiocytosisNew England Journal of Medicine, 1989
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaNew England Journal of Medicine, 1989
- Etoposide (VP16) in the treatment of multisystem langerhans cell histiocytosis (histiocytosis X)Medical and Pediatric Oncology, 1989
- Langerhans' cell histiocytosis (Histiocytosis X): Experience at the children's hospital of philadelphia, 1970–1984Medical and Pediatric Oncology, 1989
- Natural history of histiocytosis X: A pediatric oncology group studyMedical and Pediatric Oncology, 1986